Figure 5. STE-mediated disruption and degradation of microtubules in HepG2 and A549 cells.

Cultured HepG2 and A549 cells were treated with different doses of STE (0 to 400 µg/ml of STE). After 24 h treatment, cells were incubated with mouse monoclonal anti-α-tubulin antibody and corresponding rhodamine tagged secondary antibody for HepG2 cells and mouse monoclonal anti-α-tubulin antibody conjugated with FITC. Images of the untreated and STE-treated HepG2 cells (A) and A549 cells (B) were captured by a Ziess confocal microscope, LSM 510 meta. Western blot analysis against tubulin and actin proteins in HepG2 cells (C) and A549 cells (D) treated with STE (0–400 µg/ml) using mouse monoclonal anti-α-tubulin and rabbit monoclonal anti-β-actin antibodies. Data are represented as best of three independent experiments.